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Abstract
Background: Elevations of hepatic transaminase (serum alanine transaminase [ALT] and serum 
aspartate aminotransferase [AST]) levels in patients with acute coronary syndrome (ACS), although 
transient, may result in exclusions from clinical efficacy trials due to suspected liver disease. The aim 
of this study was to evaluate the concentrations of serum transaminases in ACS and relate these to cur-
rently accepted AST/ALT exclusion criteria from clinical trials.
Methods: One hundred consecutive patients with ACS were prospectively examined. Blood samples 
for AST, ALT, total bilirubin and troponin I concentration were obtained at the time of admission and 
after 6, 12 and 24 hours.
Results: Eighty percent of patients had elevated AST, and 47% ALT; 43% of patients characterized 
AST concentration > 3 × upper limit of normal (ULN) in at least one measurement, while 8% of 
patients presented ALT concentration > 3 × ULN. AST presented higher concentrations when com-
pared to ALT, resulting in a high De-Ritis ratio at every time point. No significant or high correlations 
were found between the concentrations of serum transaminases, De-Ritis ratio and troponin I. Two 
different cut-off values of troponin I were adopted to define the amount of infarcted myocardium that 
distinguished 28–31% of individuals with “large infarction”. Among these patients, approximately 93% 
presented AST concentrations > 3 × ULN.
Conclusions: Hepatic transaminases are often elevated in ACS, with the majority of patients with 
more extensive myocardial injury presenting high concentrations of AST. In the setting of ACS, current 
transaminase thresholds for liver dysfunction used in clinical trials may lead to excessive and inad-
equate exclusions of patients with larger infarcts from such trials. (Cardiol J)
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Serum alanine transaminase (ALT) and serum 
aspartate aminotransferase (AST) are routinely 
used in clinical practice as basic markers of liver 
injury. ALT is predominantly derived from hepato-
cytes — which is a specific serum marker of liver 
disease. AST is derived not only from the liver, 
but also from the heart, red blood cells, skeletal 
muscles, kidney and is elevated after ischemic cell 
death in these tissues.
Apart from liver disease, these enzymes are 
often elevated in patients with acute coronary 
syndromes (ACS) [1], most commonly as a result 
of myocardial injury, but it is also a consequence 
of low cardiac output and arterial hypoperfusion. 
In 1954, AST was the first cardiac biomarker to 
be applied to aid diagnosis of acute myocardial 
infarction, but due to lack of specificity for cardiac 
tissue, it does not remain in use [2, 3]. Elevation in 
transaminases following ACS is usually transient 
and returns to normal limits within several days 
unless there is ongoing hemodynamic compromise 
or a low output state.
Liver tests, in particular ALT, AST and total 
bilirubin are still the key safety laboratory pa-
rameters used in controlled clinical trials (CCT) 
to screen for hepatic dysfunction [4]. Numerous 
studies require the exclusion of participants with 
AST or ALT that is 2–2.5 or 3 × upper limit of 
normal (ULN). This practice is based on “Hy’s 
Law”, articulated in 1999 — a recommendation to 
use a screening threshold of liver tests for use in 
CCT (ALT or AST > 3 × ULN and total bilirubin 
> 2 × ULN, that is not primarily cholestatic and 
is not caused by disease but by the drug) [5]. This 
recommendation is often misunderstood by trial-
ists or regulatory authorities, as the vast majority 
of exclusion criteria are based only on the above-
mentioned laboratory thresholds. It is noteworthy 
that elevated transaminases may reflect injury of 
liver cells, if injured, but not the severity of liver 
dysfunction and in case of AST, may have been 
derived from other tissues. Liver dysfunction 
then must be measured by other tests and take 
into account the clinical context, in terms of other 
possible causes or patient hepatic risk factors.
Significant elevation of AST and ALT levels 
during ACS, although transient, may result in 
exclusion of substantial numbers of patients from 
clinical efficacy trials and substantial selection 
bias. Moreover, the studies indicate that if no other 
causes of liver injury are identified, the elevations 
of serum transaminases are associated with more 
severe myocardial damage, systolic dysfunction 
and higher cardiac-related mortality in ACS pa-
tients [6]. Thus, participants in such clinical trials 
that exclude those with raised transaminases may 
not represent a real-world population with the 
disease. 
The goal of the present study was to evaluate 
the concentrations of serum liver transaminases 
in patients with ACS in contemporary practice and 
attempt to indicate the subgroup of patients that 
might be hypothetically eligible for clinical trials, 
irrespective of conventionally accepted AST/ALT 
exclusion criteria.
Methods 
In this single-center observational study, 100 
consecutive patients with ACS were examined and 
admitted to the Cardiology Department of Uni-
versity Hospital No. 1 in Bydgoszcz, Poland, from 
July 1, 2018 to February 28, 2019. Patients were 
treated for ST-elevation and non-ST elevation 
myocardial infarction (STEMI and NSTEMI) in 
accordance with dedicated guidelines of the Eu-
ropean Society of Cardiology. The study protocol 
complies with the declaration of Helsinki and was 
approved by the local ethics committee of Nicolaus 
Copernicus University in Torun, Poland.
Peripheral blood samples for AST, ALT, AST/ 
/ALT ratio (De-Ritis) and troponin I concentrations 
were obtained at the time of admission and after 
6, 12 and 24 hours following admission. Total bili-
rubin concentrations were assessed at admission 
and after 24 hours. According to local guidelines, 
an abnormal ALT level was defined as a serum 
concentration > 50 U/L for men and 40 U/L for 
women; for AST > 40 U/L and > 35 U/L, respec-
tively. Enzyme activities were measured at a local 
laboratory using commercially available enzymatic 
assays (Roche Diagnostics, Austria).
Statistical analysis
The normality of the distribution was verified 
using the Shapiro-Wilk test. Continuous variables 
are presented as median and interquartile range 
(IQR) or mean ± standard deviation (SD), cat-
egorical variables as absolute frequencies and per-
centages. The comparison between two variables 
was performed with the Mann-Whitney U test or 
appropriate Student t-test according to the distri-
bution. For comparison of more than two variables 
the Kruskal-Wallis test or ANOVA was used based 
on the normality of data distribution. Analyses of 
correlations were performed using the Pearson 
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or Spearman test as required. A two-sided p value 
< 0.05 was considered significant. STATISTICA 
version 13.1 was used to perform the analyses.
Results 
Baseline characteristics of the group are 
presented in Table 1. History of liver disease or 
known alcohol addiction was noted in only 5 and 
2 individuals, respectively. Amongst patients with 
documented prior liver disease, patients mainly 
suffered from liver cirrhosis (n = 3), or previous 
hepatitis type B (n = 1) or C (n = 1). All STEMI 
patients were treated with primary percutaneous 
coronary intervention (PCI). Of those presenting 
with NSTEMI, 20% were treated with a non-inva-
sive strategy, 77% with PCI and 3% with coronary 
artery bypass grafting.
Using the definitions of abnormal transami-
nase levels described previously, 80% of patients 
had elevated AST, and 47% had elevated ALT in 
at least one measurement. In the current study 
population, 43% of patients had at least one AST 
concentration > 3 × ULN, while 8% of patients 
had at least one ALT concentration > 3 × ULN. 
Mean baseline bilirubin concentration was 0.68 
(0.51) mg/dL (normal range 0.2–1.1 mg/dL) and 
did not differ from concentrations at 24 hours (0.89 
[0.43], p > 0.05).
Concentrations of troponin I are presented in 
Figure 1. Transaminase concentrations began to 
rise during first 6 hours from admission, reaching 
a peak mostly at 12 hours (Figs. 2, 3). Elevation of 
AST levels were higher than ALT, resulting in high 
De-Ritis ratio at every time point (Fig. 4). Elevation 
of AST concentration > 3 × ULN was detected in 
13% of patients at the time of admission, in 34% of 
patients at 6 hours, in 43% at 12 hours and in 38% of 
cases 24 hours post-admission. Similar to AST, the 
concentrations of ALT > 3 × ULN were detected 
in 4% of patients at the time of admission, in 8% 
of patients at 6 hours, 6% of patients at 12 hours 
and in 4% of patients at 24 hours post-admission.
Serum concentrations of troponin I correlated 
with ALT (r = 0.60, p < 0.001), AST (r = 0.86, 
Table 1. Baseline characteristics of the study 
group.
Parameter N = 100





Statin treatment prior to ACS
No 78
Yes 22
History of liver disease
No 95
Yes 5
History of alcohol abuse
No 98
Yes 2 
ACS — acute coronary syndrome; NSTEMI — non-ST segment 
myocardial infarction; STEMI — ST-segment myocardial infarction; 
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Figure 1. Median serum concentrations of troponin I at 
baseline and after 6, 12 and 24 hours from admission; 



























6 h 12 h 24 h
Figure 2. Median serum concentrations of aspartate 
aminotransferase (AST) at baseline and after 6, 12 and 
24 hours from admission; p < 0.001, Friedman ANOVA; 
ULN — upper limit of normal.
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p < 0.001) and De-Ritis ratio (r = 0.71, p < 0.001). 
Based on these results, the aim was to assess AST 
and ALT levels in relation to infarct size, estimated 
by troponin I release. Peak values of troponin, AST 
and ALT were observed mostly at 12 hours from 
admission; thus, the analyses were performed at 
this time point. For the purpose of this study, two 
different cut-off values of troponin I were adopted 
to define the amount of infarcted myocardium, 
named “large infarction”: 1) troponin I concentra-
tion > 50 000 ng/L; 2) troponin I concentration ≥ 3rd 
quartile, that is ≥ 4111.9 ng/L. Based on this defini-
tion, 28–31% of the patients had “large infarction”. 
Among these patients, approximately 93% had AST 
concentration > 3 × ULN. The same analysis was 
performed for ALT. Results are shown in Table 2. 
Discussion
Consistent with other authors, it was con-
firmed that in the present diagnostic and treatment 
era of ACS, transaminase elevation commonly 
occurs. Moreover, it was confirmed that the rela-
tion of transaminase concentration to enzymatic 
estimations of infarct size, as defined by troponin I 
level. The present study documents that the ma-
jority of patients with more extensive myocardial 
injury present with high concentrations of AST, 
above 3 times ULN. Based on these results, the 
use of conventionally-accepted biochemical exclu-
sion criteria for liver dysfunction, adopted for the 
purpose of clinical trials, would result in exclusion 
of 13–43% of patients with ACS from clinical tri-
als during the first 24 hour post-admission. Taken 
together, despite the small sample size of the cur-
rent study, it was shown that currently used criteria 
for liver dysfunction may not mirror liver-specific 
dysfunction in the setting of ACS and may not be 
suitable. 
Elevated serum transaminase activity in ACS 
patients has been ascribed to hypoxic liver injury 
(HLI) [7, 8]. Circulatory failure in ACS (arterial 
hypoperfusion, low cardiac output) directly influ-
ence hepatic blood flow, resulting in hepatocellular 
dysfunction and elevation of AST and ALT. It is 
usually a transient and reversible condition. The 
typical laboratory finding in HLI is the elevation 
Figure 4. De-Ritis ratio (aspartate aminotransferase/ala-
nine transaminase [AST/ALT]) at the time points: at 
baseline and after 6, 12 and 24 hours from admission. 
De-Ritis ratio calculated when AST or/and ALT concen-
tration was above the upper limit of normal (n = 42).
Table 2. Proportions of patients with “large infarction” and significantly elevated aspartate aminotrans-
ferase (AST), alanine transaminase (ALT) concentrations as well as De-Ritis ratio > 1.
Definition of  
large infarction
Definition met 
(number of  
patients)
Proportion of  
patients with AST 
level > 3 × ULN
Proportion of  
patients with ALT 
level > 3 × ULN
Proportion of  
patients with  
De-Ritis ratio > 1
Troponin I > 50 000 ng/L 28 92.9% (26) 17.9% (5) 28 (100%)
Troponin I ≥ 3rd quartile 31 93.5% (29) 16.1% (5) 31 (100%)






















































6 h 12 h 24 h
Figure 3. Median serum concentrations of alanine 
transaminase (ALT) at baseline and after 6, 12 and 24 
hours from admission; p < 0.001, Friedman ANOVA; 
ULN — upper limit of normal.
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in transaminase and lactate dehydrogenase (LDH) 
levels. Transaminase and LDH levels peak 1–3 days 
after the acute event and return to normal within 
7–10 days, unless there is persistent hemodynamic 
compromise. Other laboratory findings are mild 
elevations of serum bilirubin, alkaline phosphatase 
and prolongation of prothrombin time. Neverthe-
less, HLI alone cannot explain the elevation in 
transaminases observed in ACS patients. It is now 
evident that AST and ALT release in these patients 
is attributed primarily to myocardial rather than 
hepatic origin [1, 9]. In the present study, AST 
concentrations were relatively higher than ALT 
concentrations, resulting in high De-Ritis ratio at 
every time point. Moreover, the correlation between 
AST and troponin I, was greater than that between 
ALT and troponin. These findings directly indicate 
predominant extrahepatic origin of AST release.
It is clear that, for the purposes of clinical 
trials, elevation in transaminase levels cannot, in 
isolation, be used to identify hepatic dysfunction, in 
part due to the important myocardial source of such 
enzyme rise as well as the reversible nature of such 
enzymatic fluctuations in patients with ACS. With 
regard to the ACS population, the conventionally-
accepted transaminase threshold values accepted for 
clinical trials [10, 11] seem to be too low and likely 
result in exclusion of patients with a primary cardiac 
cause for such enzyme elevation, without primary 
hepatic dysfunction. The differential diagnosis of 
serious liver insufficiency in ACS patients requires 
more clinical and laboratory investigation, including 
functional assessment of liver synthesis including 
tests of coagulation and albumin, as well as repeti-
tive testing. The present study demonstrated that 
when troponin, AST and ALT concentrations were 
elevated, the De-Ritis ratio was high.
This study shows that 93% of ACS patients 
with severe myocardial injury as defined by tro-
ponin I level, have transaminase levels elevated 
> 3 times ULN. As far as the accepted liver-based 
screening criteria for CCT are concerned, it ap-
pears that a significant group of patients may be 
excluded from dedicated clinical trials. Moreover, 
the rest of participants may not be representative of 
the real-world population with the disease [12–14]. 
On the other hand, recent evidence suggests that 
elevated serum transaminases are associated with 
more severe myocardial damage along with worse 
short- and long-term clinical outcomes [6, 15, 16]. 
Regarding the prognostic potential of transami-
nases in ACS patients, particularly in relation to 
the severity of myocardial damage, accepted he-
patic biochemistry-based exclusion criteria might 
limit the participation of high-risk patients in such 
trials. If clinical trials enroll only a highly selected 
population, the results may not be generalized 
to individuals at higher risk [17, 18]. There is, 
therefore, a gap in adequate recommendations for 
patient subgroups who are the highest risk and who 
may benefit most from new interventions in CCT.
Limitations of the study
The present study is limited mainly by the sin-
gle center setting and the relatively small sample 
size. Additionally, it was not possible to sufficiently 
report the time intervals between symptom onset 
and hospital admission. Thus, enzyme dynamics 
may not reflect real ACS time course. Although this 
study is not representative of all ACS patients, it 
was assumed that it was sufficient to address im-
portant concerns regarding CCT exclusion criteria 
commonly used in these settings.
Conclusions
In conclusion, it was shown that accepted AST 
and ALT exclusion thresholds for liver dysfunction, 
adopted for the purpose of CCT, may not mirror 
liver-specific dysfunction in the setting of ACS. If 
data management in clinical trials are influenced 
by the clinical context in which each study drug 
or intervention will be used, there is a need for 
re-evaluation of existing biochemistry screening 
criteria for liver dysfunction in ACS patients. Such 
revised criteria would allow inclusion of more 
individuals at higher risk, and reduce the number 
of patients who screen-fail in CCT and who may 
therefore benefit from the studied intervention. 
Revision or expansion of eligibility criteria might, 
however, increase the heterogeneity of the study 
population, but this is likely to be offset by the 
greater benefit: risk ratio that is likely to be ob-
served in the highest risk patients. 
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